102 related articles for article (PubMed ID: 21187034)
1. [CDK4, a specific target in the treatment of lung adenocarcinomas mutated for KRAS].
Dubus P
Med Sci (Paris); 2010 Dec; 26(12):1023-5. PubMed ID: 21187034
[No Abstract] [Full Text] [Related]
2. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
3. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
[TBL] [Abstract][Full Text] [Related]
4. [CRAF, a key player in lung adenocarcinomas induced by K-Ras oncogene].
Francoz S; Dubus P
Med Sci (Paris); 2011 Oct; 27(10):820-2. PubMed ID: 22027418
[No Abstract] [Full Text] [Related]
5. KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.
Guibert N; Ilie M; Long E; Hofman V; Bouhlel L; Brest P; Mograbi B; Marquette CH; Didier A; Mazieres J; Hofman P
Curr Mol Med; 2015; 15(5):418-32. PubMed ID: 25941815
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
[TBL] [Abstract][Full Text] [Related]
7. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
8. Cyclin-dependent kinases as therapeutic targets in melanoma.
Miller DM; Flaherty KT
Pigment Cell Melanoma Res; 2014 May; 27(3):351-65. PubMed ID: 24405945
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle inhibitors make progress.
Brower V
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 25006194
[No Abstract] [Full Text] [Related]
10. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.
Mao CQ; Xiong MH; Liu Y; Shen S; Du XJ; Yang XZ; Dou S; Zhang PZ; Wang J
Mol Ther; 2014 May; 22(5):964-73. PubMed ID: 24496383
[TBL] [Abstract][Full Text] [Related]
11. [Responses to targeted therapies: lung cancer].
Brambilla E
Ann Pathol; 2009 Nov; 29 Spec No 1():S77-80. PubMed ID: 19887261
[No Abstract] [Full Text] [Related]
12. Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
Son KH; Kim MY; Shin JY; Kim JO; Kang JH
Anticancer Res; 2021 Oct; 41(10):4807-4820. PubMed ID: 34593430
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.
Salvador-Barbero B; Álvarez-Fernández M; Zapatero-Solana E; El Bakkali A; Menéndez MDC; López-Casas PP; Di Domenico T; Xie T; VanArsdale T; Shields DJ; Hidalgo M; Malumbres M
Cancer Cell; 2020 Mar; 37(3):340-353.e6. PubMed ID: 32109375
[TBL] [Abstract][Full Text] [Related]
14. Small RNA combination therapy for lung cancer.
Xue W; Dahlman JE; Tammela T; Khan OF; Sood S; Dave A; Cai W; Chirino LM; Yang GR; Bronson R; Crowley DG; Sahay G; Schroeder A; Langer R; Anderson DG; Jacks T
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3553-61. PubMed ID: 25114235
[TBL] [Abstract][Full Text] [Related]
15. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma.
Okudela K; Hayashi H; Ito T; Yazawa T; Suzuki T; Nakane Y; Sato H; Ishi H; KeQin X; Masuda A; Takahashi T; Kitamura H
Am J Pathol; 2004 Jan; 164(1):91-100. PubMed ID: 14695323
[TBL] [Abstract][Full Text] [Related]
16. After decades, progress against an 'undruggable' cancer target.
Kaiser J
Science; 2019 Nov; 366(6465):561. PubMed ID: 31672875
[No Abstract] [Full Text] [Related]
17. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Mayer EL
Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
[No Abstract] [Full Text] [Related]
18. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
19. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
Pang X; Liu M
Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
[TBL] [Abstract][Full Text] [Related]
20. KRAS as a Therapeutic Target.
McCormick F
Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]